Literature DB >> 2422205

Continuous production of a cytopathic human T-lymphotropic virus in a permissive neoplastic T-cell line.

J P Getchell, J L Heath, D R Hicks, C Sporborg, C R McGrath, V S Kalyanaraman.   

Abstract

We developed cloned populations from the commonly available, well-characterized cell line HUT-78. These cloned cells grow permanently after infection with isolates of human T-lymphotropic virus type III, also called lymphadenopathy virus (HTLV-III/LAV), from patients with acquired immune deficiency syndrome and related syndromes. In contrast, activated human T cells are lysed after HTLV-III/LAV infection. The infected cloned cells have been in culture continuously for 6 months and have produced high levels of extracellular reverse transcriptase (400,000 cpm/ml). This level is comparable to that of similarly infected normal human T cells. Three weeks after infection with HTLV-III/LAV, more than 90% of the cloned HUT-78 cells lysed; the remaining cells continued to grow. Approximately 80% of these cells expressed HTLV-III/LAV antigens by immunofluorescence. The extracellular virus of the chronically infected cell line was shown to be similar to other HTLV-III/LAV isolates by competition radioimmunoassay, by reactivity with human serum, and by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This HTLV-III/LAV-infected immortalized cell line enables the continuous production of large amounts of virus.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2422205      PMCID: PMC362827          DOI: 10.1128/jcm.23.4.737-742.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Functional and morphologic characterization of human T cells continuously grown in vitro.

Authors:  F W Ruscetti; D A Morgan; R C Gallo
Journal:  J Immunol       Date:  1977-07       Impact factor: 5.422

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia.

Authors:  B J Poiesz; F W Ruscetti; M S Reitz; V S Kalyanaraman; R C Gallo
Journal:  Nature       Date:  1981-11-19       Impact factor: 49.962

5.  Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas.

Authors:  A F Gazdar; D N Carney; P A Bunn; E K Russell; E S Jaffe; G P Schechter; J G Guccion
Journal:  Blood       Date:  1980-03       Impact factor: 22.113

6.  Lymphadenopathy associated virus infection of a blood donor--recipient pair with acquired immunodeficiency syndrome.

Authors:  P M Feorino; V S Kalyanaraman; H W Haverkos; C D Cabradilla; D T Warfield; H W Jaffe; A K Harrison; M S Gottlieb; D Goldfinger; J C Chermann
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

7.  Isolation and transmission of human retrovirus (human t-cell leukemia virus).

Authors:  M Popovic; P S Sarin; M Robert-Gurroff; V S Kalyanaraman; D Mann; J Minowada; R C Gallo
Journal:  Science       Date:  1983-02-18       Impact factor: 47.728

8.  Immunological properties of a type C retrovirus isolated from cultured human T-lymphoma cells and comparison to other mammalian retroviruses.

Authors:  V S Kalyanaraman; M G Sarngadharan; B Poiesz; F W Ruscetti; R C Gallo
Journal:  J Virol       Date:  1981-06       Impact factor: 5.103

9.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

View more
  8 in total

1.  Heterosexual and perinatal transmission of human immunodeficiency virus in a low prevalence community.

Authors:  A F Taylor; S Johnson; S R Wyant; D E Dassey
Journal:  West J Med       Date:  1988-02

2.  HIV antigen stimulates basophil leukocytes from AIDS patients to release histamine due to type I allergy.

Authors:  M Pedersen; C M Nielsen; H Permin; S Norn
Journal:  Agents Actions       Date:  1989-04

3.  Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.

Authors:  T C VanCott; J R Mascola; R W Kaminski; V Kalyanaraman; P L Hallberg; P R Burnett; J T Ulrich; D J Rechtman; D L Birx
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

4.  Antigen-antibody reaction in solution in capture competition immunoassay for human immunodeficiency virus antibodies.

Authors:  C M Nielsen; B Kvinesdal; B F Vestergaard
Journal:  J Clin Microbiol       Date:  1989-07       Impact factor: 5.948

5.  Establishment of a feline T-lymphoblastoid cell line highly sensitive for replication of feline immunodeficiency virus.

Authors:  T Miyazawa; T Furuya; S Itagaki; Y Tohya; E Takahashi; T Mikami
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

6.  Natural killer cell-mediated lysis of T cell lines chronically infected with HIV-1.

Authors:  S Bandyopadhyay; U Ziegner; D E Campbell; D S Miller; J A Hoxie; S E Starr
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

7.  Significance of premature stop codons in env of simian immunodeficiency virus.

Authors:  T Kodama; D P Wooley; Y M Naidu; H W Kestler; M D Daniel; Y Li; R C Desrosiers
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

8.  A time-of-drug addition approach to target identification of antiviral compounds.

Authors:  Dirk Daelemans; Rudi Pauwels; Erik De Clercq; Christophe Pannecouque
Journal:  Nat Protoc       Date:  2011-06-02       Impact factor: 13.491

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.